Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€7.65

€7.65

4.030%
0.3
4.030%
€26.70
 
19.09.24 / Tradegate WKN: A2JMQW / Symbol: SRRK / Name: Scholar Rock / Stock / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Scholar Rock Holding Stock

A very strong showing by Scholar Rock Holding today, with an increase of €0.30 (4.030%) compared to yesterday's price.
Scholar Rock Holding is currently one of the favorites of our community with 16 Buy predictions and no Sell predictions.
Based on the current price of 7.65 € the target price of 26 € shows a potential of 239.87% for Scholar Rock Holding which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Scholar Rock Holding stock. Negative votes have not been in the majority for any criteria for this stock

Scholar Rock is a clinical-stage biopharmaceutical company that engages in the discovery and development of innovative medicines to treat serious diseases in patients that currently have limited or no treatment options. Their pipeline consists of a number of product candidates that target growth factor signaling pathways within the human body. These products hold potential for the treatment of multiple diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock, which trades under the symbol SRRK, is listed on the NASDAQ stock exchange.

Pros and Cons of Scholar Rock Holding in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

When diving into the financials of Scholar Rock (SRRK), a company in the biopharmaceutical sector, the immediate impression is a mix of promise and concern. Although it’s pushing the boundaries of innovation in the life sciences with its potential therapies, the current financial metrics present a rather challenging picture. The combination of a budding market capitalization, lacking revenue, and significant losses raises questions about its short-term viability and long-term growth prospects.

*Pros: *

Market Capitalization: At approximately $656 million, Scholar Rock represents a company that, despite its financial struggles, holds a stable position within the market. A significant market cap often indicates investor interest and confidence in future growth, possibly driven by its clinical developments and pipeline candidates.

Comments

The comment is under review

Prediction Buy
Perf. (%) -0.65%
Target price 28.014
Change
Ends at 25.06.25

Scholar Rock Holding Co. (NASDAQ: SRRK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Ratings data for SRRK provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -13.07%
Target price 28.787
Change
Ends at 13.06.25

Scholar Rock Holding Co. (NASDAQ: SRRK) had its price target raised by analysts at BMO Capital Markets from $29.00 to $31.00. They now have an "outperform" rating on the stock.
Ratings data for SRRK provided by MarketBeat
Show more

News

Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity: https://mms.businesswire.com/media/20211102005274/en/922183/5/Logo_2020.jpg
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity


Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer: https://mms.businesswire.com/media/20211102005274/en/922183/5/Logo_2020.jpg
Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer


Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious

Scholar Rock to Participate in Upcoming Investor Conferences: https://mms.businesswire.com/media/20211102005274/en/922183/5/Logo_2020.jpg
Scholar Rock to Participate in Upcoming Investor Conferences


Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious